On January 14, 2026, Zhejiang Daoer Biotechnology Co., Ltd. (hereinafter referred to as "Daoer Biotechnology"), a subsidiary of East China Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), received a notification from the US Food and Drug Administration (hereinafter referred to as "the US FDA") that the clinical trial application for DR10624 injection drug submitted by Daoer Biotechnology has been approved by the US FDA and can be conducted in the United States. The indication is Metabolic Dysfunction Associated Stem Liver Disease (MASLD).
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
(4)Spray
(5)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
We provide tirzepatide powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/news/peptides-price-list-of-bloom-tech-85355837.html
DR10624 is the world's first (First: in class) long-acting three specific agonist independently developed by Doer Biotech, targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon like peptide-1 receptor (GLP-1 R). DR10624 is a chimeric peptide targeting GLP-1R/GCGR at the N-terminus, fused with an engineered IgG1 Fc, and fused with a recombinant FGF21 mutant at the C-terminus of the Fc.
DR10624 injection has successfully completed the Phase I clinical study of severe hypertriglyceridemia (SHTG) and obtained positive top line results after exposure. Previously, the results of the New Zealand Phase b/a clinical study of DR10624 for the treatment of obesity combined with hypertriglyceridemia, which was presented at the EASL Congress 2025, showed a reduction in liver lipid levels of up to 89% and a relative decrease in triglycerides of over 70% compared to baseline.
In November 2025, the results of the Phase I1 clinical study of DR10624 for the treatment of severe hypertriglyceridemia ("DR10624-201 study") were announced at AHA Scientific Sessions 2025. After 12 cycles of treatment, compared to placebo, all dose groups of DR10624 achieved significant reductions in triglyceride levels, with a median percentage decrease of up to 74.5%; Meanwhile, compared to the placebo group, the liver fat content of all DR10624 dose groups was significantly reduced, with a median percentage decrease of up to 67%.
Gan Li Pharmaceutical Ondibta has been approved by the European Union to enter the European market
On January 14, 2026, Ganli Pharmaceutical Co., Ltd. (hereinafter referred to as Ganli Pharmaceutical, stock code: 603087. SH) and its wholly-owned European subsidiary Gan&LeePharmaceuticals Europe GmbH (hereinafter referred to as "Ganli Europe") announced that the Ganjing Insulin Injection (European trade name: Ondibta, Chinese trade name: Chang Xiulin), independently developed by Ganli Pharmaceutical, had recently been approved by the European Commission (EC) to treat diabetes in adults, adolescents and children aged 2 years and above.
This approval marks the official entry of Ganli Pharmaceutical's Ganjing Insulin Injection into the European market, which will be launched and sold in the European Union (EU), Iceland, Liechtenstein, and Norway.
Ganjing membrane insulin is a long-acting basic insulin analog, which is injected subcutaneously once a day and has a hypoglycemic effect lasting for 24 hours. It has the characteristics of long action time, stable and non peak blood drug concentration, and stable sugar control.
As of now, Chang Xiulin from Ganli Pharmaceutical is the first and only domestically produced glargine insulin in China to complete head to head clinical trials with the original reference drug (Sanofi: Lantus) in Europe and the United States.
In more than 1100 patients with diabetes (including about 580 patients with type 1 diabetes and 570 patients with type 2 diabetes), it is fully confirmed that Changxiu Lin "/0ndibta" is completely equivalent to the original reference drug in terms of efficacy and safety.
At the same time Using the "glucose clamp" technique, which is the gold standard for evaluating insulin drugs, Ganli Pharmaceutical has also conducted and completed a head to head clinical study of Ganli Ganjing Insulin U300 and the original research (Sanofi: Laiyushi), confirming that the two are completely equivalent in terms of efficacy and safety.
potential uses
Currently, research is exploring the application of Tirzepatide in the treatment of NASH. Due to Tirzepatide's ability to regulate glucose and lipid metabolism, reduce fat accumulation, and improve insulin resistance, these mechanisms of action may be beneficial for the treatment of NASH. NASH is closely related to metabolic diseases such as obesity and diabetes. While improving metabolic indicators, Tirzepatide may help reduce liver steatosis and inflammatory reaction, thus delaying the progress of NASH.
Tirzepatide is also conducting clinical trials in the treatment of sleep apnea syndrome. Obesity is an important risk factor for sleep apnea syndrome. Tirzepatide, through its weight loss effect, may reduce neck fat accumulation, improve upper airway patency, and alleviate symptoms of sleep apnea. At the same time, its regulatory effect on metabolism may also help improve the overall health status of patients and enhance sleep quality.
Potential role in the treatment of chronic kidney disease
There are studies indicating that Tirzepatide may have a certain therapeutic effect on chronic kidney disease. It can lower blood pressure, reduce inflammatory reactions, improve renal hemodynamics, and thus protect renal function. In animal experiments, Tirzepatide may reduce the risk of liver and kidney complications, providing some basis for its application in the treatment of chronic kidney disease.